Hepatitis C virus antibodies
The Hepatitis C virus antibodies supplied by The Native Antigen Company recognise structural and non-structural proteins produced by Hepatitis C virus. The Hepatitis C virus antibodies are suitable for use in immunoassay research and development.
Hepatitis C virus (HCV) is an enveloped, positive-sense, single stranded RNA virus that is a member of the hepacivirus genus of the family Flaviviridae. HCV was first recognised in 1970 and described as non-A, non-B hepatitis, until 1989 when the pathogen was identified as hepatitis C. The structural proteins produced by Hepatitis C virus include the core protein and envelope glycoproteins E1 and E2, which are necessary for viral entry into host cells. Non-structural (NS) proteins include V7 viroporin and NS2 protease, which play essential roles in viral infection and replication, and NS3, NS4a, NS4b and NS5b proteins.
Currently, eleven genotypes of HAV are recognised, designated 1-11. Genotypes 1-6 are the major genotypes, which are further classified into subtypes a,b and c. Genotype 1 is the most prevalent globally, followed by 3, 2 and 4.
Humans are the primary reservoir of Hepatitis C virus. HCV is a bloodborne virus that is transmitted through infected blood. Transmission of HCV may occur through the sharing of needles for injecting drugs, the use of inadequately sterilised medical equipment infected with HCV and the transfusion of unscreened blood and blood products. HCV is responsible for 15-20% of cases of acute hepatitis worldwide (WHO).
All recognised genotypes are pathogenic and target hepatocytes. The incubation period for HCV infection is 2-6 months. During the period of acute infection, most individuals remain asymptomatic and recover without need for treatment but may present with liver damage later in life. A large percentage of HCV infected Individuals have clinical symptoms that include nausea, vomiting, fatigue, abdominal pain and jaundice. Patients may also develop chronic hepatitis, which can progress to cirrhosis or hepatocellular carcinoma. Additional complications associated with persistent HCV infection include insulin resistance and type II diabetes mellitus (Li, HC).
The different genotypes of HCV respond differently to treatment and therefore a correct diagnosis is important. However, Hepatitis C virus is difficult to isolate, and the asymptomatic nature of HCV infection makes clinical diagnosis difficult. Serological methods to detect HCV IgM antibodies in patient’s serum are reported to be unreliable but diagnostic methods to detect HCV total antibody and HCV core protein may have some value.
World Health Organization: Hepatitis C, key facts
Li HC et al. 2015. Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol. 8;7(10):1377-89.
Showing 1–10 of 18 results
Mouse anti Hepatitis C virus core protein antibody (1851)$285.20 Select options
Mouse anti Hepatitis C virus core protein antibody (1862)$285.20 Select options
Mouse anti Hepatitis C virus core protein antibody (1863)$285.20 Select options
Mouse anti Hepatitis C virus core protein antibody (1864)$285.20 Select options
Mouse anti Hepatitis C virus core protein antibody (1868)$285.20 Select options
Mouse anti Hepatitis C virus E1 antibody (1879)$285.20 Select options
Mouse anti Hepatitis C virus E2 antibody (1876)$285.20 Select options
Mouse anti Hepatitis C virus NS3 antibody (1828)$285.20 Select options
Mouse anti Hepatitis C virus NS3 antibody (1859)$285.20 Select options
Mouse anti Hepatitis C virus NS3 antibody (1878)$285.20 Select options
We hold good stocks of all our antigens to ensure a rapid delivery service worldwide. We like to be in touch with our customers so please drop us a line or give us a call on +44 (0)1865 595230. To place an order, please email firstname.lastname@example.org and for further information including price inquiries, bulk preparations and contract services email: email@example.com.